The global biopharmaceutical CMO and CRO market size is expected to reach USD 54.1 billion by 2030, registering a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Post-pandemic the market is being driven by the growing interest of conventional drug developers in the biological therapeutics. At present, outsourcing has become a cost-saving strategy for small- to medium-sized biomanufacturers, as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel. The post-pandemic recovery has started owing to positive pipeline developments across modalities.
For instance, Lonza and Moderna announced a ten-year collaboration for the commercial manufacturing of the COVID-19 vaccine. Such developments compensated for minor delays in clinical trials that occurred during the first half of 2020. The contract manufacturing organization segment is projected to unlock lucrative growth opportunities over the foreseeable future. The decline in R&D productivity and increased development costs have resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the CMOs & CROs to accelerate their business operations.
The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs. However, these CMOs & CROs are expected to face competition from in-house departments of pharmaceutical & biotechnology companies. Several big pharma companies like Novartis announced to maintain and expand their biomanufacturing processes in-house over the coming years.
Browse full report with Table of Content @ https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market
Biopharmaceutical CMO And CRO Market Report Highlights
• Non-mammalian cell line-based bioproduction system is expected to be the fastest-growing segment over the forecast period
• Innovative strategies are being implemented to identify and explore the potential of various microbes
• This can be attributed to increasing investments in research programs for the development of novel therapeutics
• The market in North America is recognized as a leader in biopharmaceutical innovations, thereby resulting in a large share of 33.97%
• Moreover, the presence of several service providers and a higher concentration & number of biopharmaceutical firms in the region supports the market growth.
• The key players are involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities.
For Requesting a Sample Copy Please Visit @ https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market/request/rs15
Biopharmaceutical CMO And CRO Market Segmentation
Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source, service, product, and region:
Biopharmaceutical CMO & CRO Source Outlook (Revenue, USD Million, 2017 – 2030)
• Mammalian
• Non-mammalian
Biopharmaceutical CMO & CRO Service Outlook (Revenue, USD Million, 2017 – 2030)
• Contract Manufacturing
• Process Development
• Downstream
• Upstream
• Fill & Finish Operations
• Analytical & QC Studies
• Packaging
• Contract Research
• Oncology
• Inflammation & Immunology
• Cardiology
• Neuroscience
• Others
Biopharmaceutical CMO & CRO Product Outlook (Revenue, USD Million, 2017 – 2030)
• Biologics
• Monoclonal antibodies (MAbs)
• Recombinant Proteins
• Vaccines
• Antisense, RNAi, & Molecular Therapy
• Others
• Biosimilars
Biopharmaceutical CMO & CRO Regional Outlook (Revenue, USD Million, 2017 – 2030)
• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Asia Pacific
• China
• India
• Latin America
• Brazil
• Middle East & Africa
• South Africa
List of Key Players of Predictive Analytics Market
• Boehringer Ingelheim GmbH.
• Lonza Group AG.
• Inno Biologics Sdn Bhd
• Rentschler Biopharma SE.
• JRS Pharma.
• Biomeva GmbH
• ProBioGen AG.
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Toyobo Co., Ltd.
• Samsung Biologics
Fill the Pre-Order Enquiry Form for the Report @ https://www.grandviewresearch.com/inquiry/4564/ibb
Browse Related Reports:
Biopharmaceutical Third Party Logistics Market Size, Share & Trends Analysis Report By Supply Chain (Cold Chain, Non-cold Chain), By Service Type (Transportation, Warehousing And Storage), By Region, And Segment Forecasts, 2021 – 2028.
About Grand View Research
Grand View Research is a U.S. & India-based market research and consultancy firm. It is headquartered in San Francisco. We provide business insights, syndicated research reports, and customized research reports to large as well as small and medium-scale enterprises. Our database features thousands of statistics and in-depth analyses on more than 45 industries. Grand View Research’s extensive database is used by Fortune 500 companies to understand the regional as well as the global business environment.
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market